Jeffrey B. Landau - 02 Feb 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Business Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Issuer symbol
CTMX
Transactions as of
02 Feb 2023
Net transactions value
$0
Form type
4
Filing time
06 Feb 2023, 15:49:44 UTC
Previous filing
12 Aug 2022
Next filing
20 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +40,000 +130% $0.000000 70,725 02 Feb 2023 Direct F1, F2
holding CTMX Common Stock 4,500 02 Feb 2023 Fidelity Traditional IRA
holding CTMX Common Stock 3,180 02 Feb 2023 Schwab ROTH IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 02 Feb 2023 Common Stock 100,000 $2.59 Direct F3
transaction CTMX Performance Stock Units (PSUs) Award $0 +75,000 $0.000000 75,000 02 Feb 2023 Common Stock 75,000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.
F2 Includes 56,274 RSUs.
F3 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date.
F4 Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.